Retatrutide reportedly doubles Ozempic's weight loss in head-to-head trial

Eli Lilly reports that its drug retatrutide produced more than double the weight loss of Ozempic's highest approved dose, plus greater A1C reduction, in a head-to-head trial. Coverage is based on the company's announcement.

Timeline

1. 28 Oct, 11:50 UTCFirst appeared on Google Trends
2. 28 Oct, 11:50 UTCLilly announces head-to-head trial results
3. 28 Oct, 11:50 UTCABC News covers retatrutide weight loss claim
4. 28 Oct, 12:20 UTCReached #1 on TrendHeat

Top sources

• ozempic versus retatrutide a1c studyGoogle Trends
• Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trialEli Lilly
• Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters
• Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight lossYahoo